Darwin Ling is the founding general partner of Good AI Capital, a venture fund focusing on early-stage AI companies in Fintech, Healthcare, and B2B SaaS.  Prior to that,  he has been an entrepreneur with multiple exits, a technologist as well as an angel investor in successful startups such as SoFi . Most recently, Darwin served as the CTO and co-founder of SmarterMe, which aims to improve sales productivity by bringing AI / Intelligence to the flow of work. Counting enterprise customers such as Danaher ( Fortune 500 medical device ), Home Depot and GE, SmarterMe was recently acquired.

Nominated as a distinguished alumnus of Purdue University, Darwin was featured as one of Purdue’s Tech Titans and is serving on the leadership board for the School of Science.

Darwin received his MBA (Honors) from the University of Chicago Booth School of Business. He also holds a BS ( Phi Beta Kappa ) with distinction in Computer Science and Mathematics and an MS in Computer Science, both from Purdue University.

As a neuroscientist, entrepreneur and inventor, Milad has a unique blend of experiences in academia, research, startups and large organizations that span across fields in artificial intelligence(AI), nanotechnology, enterprise software, life sciences, and healthcare. Milad holds the appointment of Visiting Scholar in Healthcare Engineering at the Regenstrief Center. He has worked across North America, Europe, and sub-Saharan Africa.

Prior to Good AI Capital, he was a leader in Accenture’s Global R&D and Incubation Hub where he helped launch new global products and innovative services for some of the leading pharmaceutical companies using emerging technologies such as AI, Advanced Analytics, Blockchain, IoT and design thinking methodologies.

As an entrepreneur, he served as the Chief Business Officer at Corstem, a machine learning and AI software developer specialized in cardiac imaging analysis that was acquired by Circle Cardiovascular Imaging. Milad also co-founded and was the COO of Symmetry Therapeutics, an early-stage biotech company that raised money to develop their patented drug platform to treat metabolic diseases. He was also part of the founding team at Cellaflora, a software startup that was later acquired. He is an Associate at Creative Destruction Labs, mentor for TechStars AI, advisor for Holt Accelerator and on the board of advisors for Living On One, the LA-based film production company.

As one of the youngest researchers inducted into the Sigma Xi Research Honor Society, Milad has multiple publications from his research at Purdue’s Birck Nanotechnology Center and Interfacial Multiphysics Laboratory. As a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine, Milad graduated Phi Beta Kappa with his BS (distinction) in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed graduate school in Immunology & Public Health.